Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This abstract provides summaries of multiple clinical reports on topics like macular holes with posterior uveal melanoma, hemolacria, trichotillomania management with bimatoprost, Demodex identification methods, and psychological factors in contact lens discomfort, but reports no new research findings.

Latanoprost eye drops caused excessive cheek hair growth and eyelash whitening in a woman.

This report discusses the use of intralesional cidofovir and suggests it might be a viable option for treating SCC due to its successful outcome without observed systemic toxicity in this case.

This pilot study evaluated bimatoprost ophthalmic solution 0.03% for eyebrow hair regrowth in ten female patients, but reports no new clinical results.

This study reports that applying bimatoprost ophthalmic solution 0.03% to the upper eyelid margin enhances eyelash growth by increasing length, thickness, and darkness, with a favorable safety profile.

This study reported that a single treatment with a short-pulsed 755-nm alexandrite laser effectively treated trichostasis spinulosa in patients with skin types II to V, providing rapid results with minimal pain and no recurrence during a 3-month follow-up.

This observational study reports that a TRASER device using specific wavelengths for vascular and follicular targets showed both clinical responses and histological changes, suggesting its potential as an effective vascular and hair removal tool.

This study associated ivory-colored areas observed through trichoscopy with steroid deposits in the dermis among patients with steroid-induced atrophy on the scalp.

This study reports that daily topical application of a 0.05% tretinoin solution can eliminate the hair plugs and symptoms associated with trichostasis spinulosa.

In this case report, a 60-year-old woman with eyebrow hypotrichosis experienced significant and lasting eyebrow growth after daily use of bimatoprost 0.03% solution, highlighting its potential as an effective treatment for eyebrow hair restoration.

In this randomized trial, bimatoprost 0.01% significantly improved eyebrow hair density and diameter in patients with eyebrow hypotrichosis compared to a placebo, with minimal adverse effects, suggesting it is an effective and safe treatment option.

This article reviews the usage, efficacy, side effects, and alternatives of topical bimatoprost 0.03% for dermatological applications but does not present new clinical findings.

This abstract discusses the FDA approval of Latisse (bimatoprost) for increasing eyelash growth in patients with eyelash hypotrichosis and highlights its efficacy while noting unresolved effectiveness in certain conditions and potential side effects.

This chapter reviews the use of trichoscopy in hair transplantation, offering tips for hair restoration surgeons and assisting pathologists in understanding the procedure, but reports no new clinical results.

In this nonrandomized controlled trial, tenon capsule injection of platelet-rich plasma improved capillary perfusion and may enhance short-term vision in patients with acute nonarteritic anterior ischemic optic neuropathy.

This study involved using smartphone applications and low-cost trichoscopy devices to assess various hair and scalp conditions, with diagnoses confirmed through detailed imaging during remote consultations and in-person evaluations.

This clinical study reported that while both 0.01% and 0.03% bimatoprost significantly improved eyebrow density and diameter in patients with eyebrow hypotrichosis, the 0.03% concentration was more clinically preferred by patients.

This review discusses risk factors for intraoperative floppy iris syndrome, emphasizing tamsulosin and other α1 blockers, and underscores the importance of preoperative screening to mitigate surgical complications, but it reports no new results.

In this phase 2 trial, STS01 1% significantly improved hair regrowth in patients with mild to moderate patchy alopecia areata compared to placebo, with a manageable skin irritation side effect profile.

This study developed a new suspended ointment formulation containing neomycin sulfate and triamcinolone acetonide, which showed promise for treating neurodermatitis and chronic eczema by ensuring stable composition, effective skin penetration, and no skin irritation.

In this study, researchers assessed the stability of various formulations in the TrichoConcept™ line for customized alopecia treatment. They found that the combinations remained stable from 14 to 180 days, supporting the use of these vehicles for enhancing therapeutic outcomes in hair loss treatments.

In this study using a rabbit model, higher incidences of intraoperative floppy iris syndrome were observed in animals given the α-blocker tamsulosin, suggesting a potential association with increased iris billowing during eye surgery.

This review discusses the use of trichoscopy as a valuable diagnostic and prognostic tool for various hair and scalp disorders, reporting no new clinical results.

This article discusses various aspects of trichoscopy for diagnosing hair and scalp disorders and reports no clinical results, offering guidance and highlighting pitfalls for better application of this tool by dermatologists.

In this study, the TRICHOBIOLIGHT protocol showed effectiveness in treating androgenetic alopecia and telogen effluvium, with 82.5% of 103 patients experiencing excellent to good outcomes after mesotherapy and LED photobiostimulation on the scalp.

This study reported that topical spironolactone improved lid margin vascularity, corneal fluorescein staining, and disease severity scores in patients with ocular graft-versus-host disease, suggesting a potential therapeutic role by enhancing corneal lipid production with minimal adverse effects.

This study found that prototype right heart circulatory assist devices significantly improved hemodynamics and reduced pulmonary vascular resistances in piglet models of acute hemodynamic shock.

This study validated that six out of seven tested topical formulations for alopecia are compatible for 6-month use, suggesting they may be practical for compounding pharmacies.